Abstract
Cytoprotective or neuroprotective interventions would be of value if they could block the processes leading to delayed neuronal death or if they could delay the period between the onset of ischemia and irreversible necrotic injury, thereby lengthening the period for effective reperfusion therapy. Experimental studies in cell culture systems and laboratory animals show that statins have several potential cytoprotective actions, including promotion of angiogenesis, reduction of clot formation and facilitation of clot lysis, upregulation of endothelial nitric oxide synthase, downregulation of inducible nitric oxide synthase, reduction of excitotoxicity, and modulation of the inflammatory response. Clinically, statins appear to protect against vasospasm-related ischemic injury after subarachnoid hemorrhage. There have been no prospective randomized trials aimed at determining whether statins reduce acute stroke severity, and observational studies have had inconsistent results. Although a prospective, randomized trial assessing the effect of pre-or poststroke statin treatment on initial stroke severity would be the most appropriate study design to test for this type of effect, it is unlikely that such a trial will be conducted given the benefits of these drugs in reducing the risk of cardiovascular events and stroke in high-risk populations.
Similar content being viewed by others
References and Recommended Reading
Ginsberg MD, Belayev L, Zhao W: Recruitment of the ischemic penumbra into the necrotic core. Cerebrovasc Dis 1997, 7(Suppl 5):14–18.
O’Collins VE, Macleod MR, Donnan GA, et al.: 1,026 experimental treatments in acute stroke. Ann Neurol 2006, 59:467–477.
Donnan GA: The 2007 Feinberg lecture: a new road map for neuroprotection. Stroke 2008, 39:242.
Nishimura N, Schaffer CB, Friedman B, et al.: Penetrating arterioles are a bottleneck in the perfusion of neocortex. Proc Natl Acad Sci U S A 2007, 104:365–370.
Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486–2497.
Goldstein LB, Adams R, Alberts MJ, et al.: Primary Prevention of Ischemic Stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council. Stroke 2006, 37:1583–1633.
Adams RJ, Albers G, Alberts MJ, et al.: Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2008, 39:1647–1652.
Henderson RD, Eliasziw M, Fox AJ, et al.: Angiographically defined collateral circulation and risk of stroke in patients with severe carotid artery stenosis. Stroke 2000, 31:128–132.
Kureishi Y, Luo Z, Shiojima I, et al.: The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000, 6:1004–1010.
Chen JL, Zhang ZG, Li Y, et al.: Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 2003, 53:743–751.
Pourati I, Kimmelstiel C, Rand W, Karas RH: Statin use is associated with enhanced collateralization of severely diseased coronary arteries. Am Heart J 2003, 146:876–881.
Ovbiagele B, Saver JL, Starkman S, et al.: Statin enhancement of collateralization in acute stroke. Neurology 2007, 68:2129–2131.
Laufs U, Gertz K, Huang P, et al.: Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke 2000, 31:2442–2449.
Asahi M, Huang Z, Thomas S, et al.: Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia. J Cereb Blood Flow Metab 2005, 25:722–729.
Yamada M, Huang Z, Dalkara T, et al.: Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment. J Cereb Blood Flow Metab 2000, 20:709–717.
Laufs U, Gertz K, Dirnagl U, et al.: Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res 2002, 942:23–30.
Gertz K, Laufs U, Lindauer U, et al.: Withdrawal of statin treatment abrogates stroke protection in mice. Stroke 2003, 34:551–557.
McGirt MJ, Lynch JR, Parra A, et al.: Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage. Stroke 2002, 33:2950–2956.
McGirt MJ, Pradilla G, Legnani FG, et al.: Systemic administration of simvastatin after the onset of experimental subarachnoid hemorrhage attenuates cerebral vasospasm. Neurosurgery 2006, 58:945–951.
Sillberg VA, Wells GA, Perry JJ: Do statins improve outcomes and reduce the incidence of vasospasm after aneurysmal subarachnoid hemorrhage: a meta-analysis. Stroke 2008, 39:2622–2626.
Endres M, Laufs U, Huang Z, et al.: Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 1998, 95:8880–8885.
Amin-Hanjani S, Stagliano NE, Yamada M, et al.: Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke 2001, 32:980–986.
Prinz V, Laufs U, Gertz K, et al.: Intravenous rosuvastatin for acute stroke treatment: an animal study. Stroke 2008, 39:433–438.
Choi DW: Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemic damage. Trend Neurosci 1988, 11:465–469.
Zacco A, Togo J, Spence K, et al.: 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. J Neurosci 2003, 23:11104–11111.
Bosel J, Gandor F, Harms C, et al.: Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones. J Neurochem 2005, 92:1386–1398.
Johnson-Anuna LN, Eckert GP, Franke C, et al.: Simvastatin protects neurons from cytotoxicity by up-regulating Bcl-2 mRNA and protein. J Neurochem 2007, 101:77–86.
Ortego M, Bustos C, Hernandez-Presa MA, et al.: Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 1999, 147:253–261.
Pahan K, Sheikh FG, Nam S, Singh I: Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 1997, 100:2671–2679.
Sandani AF, Dawson TM, Dawson VL: Nitric oxide synthase in models of focal ischemia. Stroke 1997, 28:1283–1288.
Kawashima S, Yamashita T, Miwa Y, et al.: HMG-CoA reductase inhibitor has protective effects against stroke events in stroke-prone spontaneously hypertensive rats. Stroke 2003, 34:157–163.
Blanco M, Nombela F, Castellanos M, et al.: Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 2007, 69:904–910.
Elkind MS, Flint AC, Sciacca RR, Sacco RL: Lipid-lowering agent use at ischemic stroke onset is associated with decreased mortality. Neurology 2005, 65:253–258.
Marti-Fabregas J, Gomis M, Arboix A, et al.: Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke 2004, 35:1117–1121.
Aslanyan S, Weir CJ, McInnes GT, et al.: Statin administration prior to ischaemic stroke onset and survival: exploratory evidence from matched treatment-control study. Eur J Neurol 2005, 12:493–498.
Bushnell CD, Griffin J, Newby LK, et al.: Statin use and sex-specific stroke outcomes in patients with vascular disease. Stroke 2006, 37:1427–1431.
Moonis M, Kane K, Schwiderski U, et al.: HMG-CoA reductase inhibitors improve acute ischemic stroke outcome. Stroke 2005, 36:1298–1300.
Reeves MJ, Gargano JW, Luo Z, et al.: Effect of pretreatment with statins on ischemic stroke outcomes. Stroke 2008, 39:1779–1785.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Goldstein, L.B. Statins and ischemic stroke severity: Cytoprotection. Curr Atheroscler Rep 11, 296–300 (2009). https://doi.org/10.1007/s11883-009-0045-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11883-009-0045-3